Cancer Prodrug Targeting CD36 for Selective Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using cytotoxic agents often result in significant side effects due to their non-selective targeting of both cancer and normal cells, limiting the dosage that can be administered effectively.
Innovation Solution
Development of prodrug compounds that selectively target cancer cells overexpressing fatty acid uptake proteins like CD36, utilizing a carboxylic acid group, a cytotoxic drug moiety, and a hydrophobic group to facilitate active targeting and reduce off-target damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cytotoxic agents are administered to kill cancer cells, then cancer cell death is improved, but side effects on normal cells increase
Solution Approach 1:
The patent uses a prodrug intermediary that requires activation by fatty acid uptake proteins (FAUPs) to become cytotoxic. The prodrug itself is not toxic, but is converted to the active cytotoxic form only within cancer cells that overexpress FAUPs, thereby mediating selective toxicity and protecting normal cells from harm
Solution Approach 2:
The patent creates local quality differences by designing a prodrug with specific lipid-like properties that enable selective accumulation in cancer cells through FAUP-mediated uptake. The activation process creates localized cytotoxicity only where FAUPs are overexpressed, making the harmful effect localized to cancer cells rather than affecting all cells uniformly
2Productivity
If higher doses of cytotoxic agents are administered to improve treatment efficacy, then cancer cell killing is improved, but harm to healthy tissue increases
Solution Approach 1:
The prodrug acts as a safe intermediary that can be administered at higher doses because it lacks cytotoxicity until activated. The activation by FAUPs ensures that even at higher doses, the cytotoxic effect is confined to cancer cells, allowing dose escalation without proportionally increasing harm to healthy tissue
3Object-affected harmful factors
If prodrugs are designed to bind to human serum albumin to decrease off-target damage, then selectivity is improved, but uptake by cancer cells may be reduced
Solution Approach 1:
The patent merges two seemingly contradictory mechanisms: albumin binding for selective delivery and FAUP-mediated uptake for cancer cell entry. The lipid-like prodrug structure enables both HSA binding (for selective transport to tumor tissue) and recognition by FAUPs (for cellular internalization), combining multiple selective targeting mechanisms in one molecule
Solution Approach 2:
The prodrug design incorporates multi-functionality by enabling both albumin binding and FAUP-mediated uptake. This universal design allows the same molecule to exploit multiple biological pathways (albumin transport system and fatty acid uptake system) to achieve selective cancer cell targeting, making it effective across different cancer types that overexpress FAUPs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The prodrug compounds demonstrate enhanced uptake by cancer cells overexpressing CD36, allowing for increased cytotoxicity specifically in cancer cells while minimizing harm to healthy tissues, thereby improving treatment efficacy and reducing side effects.
Implementation Method 1
the prodrug feature also allowed the prodrug to be taken up selectively by certain cancer cells via the overexpression of surface proteins that mediate the transport of fatty acids to the interior of the cell
Implementation Method 2
the prodrug feature did not merely improve non-covalent binding to human serum albumin (HSA) and thereby decrease off-target damage to healthy tissue
Data Source
AI summary
The present disclosure provides methods of using prodrugs of small-molecule cytotoxins for the treatment of cancer. In some embodiments, the cancer is a tumor comprising cells that overexpress fatty acid uptake proteins, such as cells that overexpress fatty acid translocase CD36. In some other aspects, the disclosure provides compositions suitable for use in such methods. In some further aspects, the disclosure provides combination therapies that may be suitable used in combination with the use of small-molecule prodrugs disclosed herein.